Harness the rising tide of transformation
Next-generation oncology care demands next-generation precision tests
We’re building upon seven years of medical-AI research to deliver AI tests that ignite biomarker discovery, streamline multimodal diagnostic workflows, and scale precision oncology for patients worldwide.
Waiv spearheads scalable AI grounded in medical science to deliver transformative tests for patients, hand-in-hand with the healthcare partners who share the same mission.
Waiv has evolved to meet this moment
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin, capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC, to unlock morphological insights and future-proof the clinical diagnostic workflow.
Building with an innovative legacy, and renewed vigor
Deep expertise in machine learning, foundation models, pathology, & oncology with a proven track record of bringing clinically validated tests to the market.
A vast international data network providing high-quality, diverse datasets that reinforce model performance, accelerate clinical translation & product validation.
Longstanding collaborations with world-class medical institutions and Biopharma to bring new targeted testing paradigms to patients.
